Hereditary thrombotic thrombocytopenic purpura, abbreviated hTTP, is caused by inherited defects in a gene called ADAMTS13, which carries the instructions for an enzyme with one of the most elegant jobs in the circulatory system. The enzyme patrols the bloodstream and slices up unusually long, sticky strands of von Willebrand factor, a protein that helps platelets clump together at sites of injury. When ADAMTS13 is missing or severely deficient, those ultra-large strands accumulate unchecked and spontaneously snag passing platelets, forming microscopic clots throughout the smallest blood vessels. The result is a cascade of problems: platelets are consumed faster than the bone marrow can replace them, red blood cells are sheared apart as they squeeze through partially blocked vessels, and vital organs, including the brain, kidneys, and heart, can be starved of oxygen by the clotting itself. Unlike the more common immune-mediated form of the disease, in which the body produces antibodies that disable a perfectly good enzyme, the hereditary form stems from mutations written directly into the genetic code.

The research team, led by Yeming Wan and Xiubin Guo as co-first authors with Mei Tan as corresponding author, retrospectively analyzed the clinical records, laboratory measurements, genetic testing results, family investigations, and treatment outcomes of the three pediatric patients. All three children presented with recurrent thrombocytopenia, meaning persistently or repeatedly low platelet counts, with or without hemolytic anemia, the destruction of red blood cells. These are precisely the features that make the disease so easy to mistake for more familiar conditions. The heterogeneous presentation of hTTP, the authors emphasize, is a central reason it is frequently misdiagnosed, and the consequences of that misdiagnosis can be serious, because the treatments for immune thrombocytopenia do nothing to address the underlying enzyme deficiency.

Laboratory testing told a decisive story once the right assays were ordered. In two of the three patients, designated Cases 2 and 3, ADAMTS13 activity measured below 5 percent of normal, a threshold that essentially rules out adequate enzyme function and points squarely toward either a hereditary defect or a severe immune-mediated shutdown of the enzyme. In Case 1, activity was recorded at 13 percent, though this measurement was taken after the patient had already received treatment, which may complicate interpretation of the value. Critically, testing for ADAMTS13 inhibitors, the autoantibodies that characterize the immune form of the disease, came back negative in all three children. That combination, profoundly reduced enzyme activity without any detectable inhibitor, is the biochemical signature of the hereditary form and provided the rationale for moving to genetic analysis.

Sequencing of the ADAMTS13 gene revealed three distinct variants across the three patients, and this is where the study makes its most durable contribution to medical knowledge. Two of the variants had never been reported before in the scientific literature. The first novel variant, written as c.1324 C>T, p.Gln442Ter, converts a codon specifying the amino acid glutamine at position 442 of the protein into a premature stop signal, a type of mutation that typically truncates the protein and destroys its function. The second novel variant, c.1459T>C, p.Cys487Arg, is subtler: it swaps a single amino acid, replacing a cysteine at position 487 with an arginine. Cysteine residues are often crucial for the three-dimensional folding of proteins because they form disulfide bonds that hold the molecular architecture together, so substituting a charged arginine for a cysteine can destabilize the enzyme or interfere with its catalytic machinery. The third variant, c.1192 C>T, p.Arg398Cys, had been reported previously and similarly replaces an arginine with a cysteine at position 398.

The inheritance patterns observed in the families add another layer of biological interest. Case 1 carried compound heterozygous mutations, meaning the child inherited two different defective copies of the ADAMTS13 gene, one from each parent: the novel nonsense variant p.Gln442Ter on one chromosome and the previously reported p.Arg398Cys on the other. Cases 2 and 3, by contrast, each carried homozygous mutations, meaning both copies of the gene carried the identical novel variant, p.Cys487Arg. Homozygosity for a rare disease-causing variant often raises the possibility of consanguinity in the family history, a pattern frequently seen in rare recessive disorders, and family investigations are a standard part of the workup for exactly this reason. Because ADAMTS13 deficiency is recessive, carriers with one normal copy typically produce enough enzyme to remain healthy, which is why these conditions can appear seemingly out of nowhere in a family with no prior history.

The clinical implications of the study reach well beyond the three patients described. The authors make an explicit recommendation that recurrent thrombocytopenia in children, particularly when there is a poor response to immune thrombocytopenia therapy, should prompt clinicians to consider evaluation for hereditary TTP. This is a message aimed at frontline pediatricians and emergency physicians, who are far more likely to see a child with low platelets than to suspect a defect in a single obscure enzyme. The diagnostic pathway the researchers describe, combining ADAMTS13 activity testing with inhibitor screening and confirmatory genetic analysis, is now the recognized gold standard for distinguishing the hereditary form from the immune form, and the distinction matters enormously for treatment decisions, prognosis, and family counseling.

Treatment of hereditary TTP has been transformed in recent years, although the source material for this case series focuses primarily on diagnosis rather than detailing long-term therapeutic regimens. Historically, the mainstay of care for acute TTP episodes of any cause was plasma exchange, in which the patient’s plasma, laden with ultra-large von Willebrand factor strands and deficient in functional enzyme, is replaced with donor plasma that supplies working ADAMTS13. For the hereditary form, regular plasma infusions can serve as prophylaxis, providing the missing enzyme on a scheduled basis. More recently, a recombinant form of the ADAMTS13 enzyme has been developed specifically for patients with the congenital form of the disease, offering a targeted replacement therapy that addresses the root cause rather than the symptoms. Immunosuppressive drugs, which are central to treating the immune form, have little role in the hereditary form because there is no antibody to suppress, underscoring why getting the diagnosis right is not an academic exercise but a decision that shapes the entire treatment strategy.

The study also highlights the practical value of expanding the global database of disease-causing variants. Every newly documented mutation, such as the p.Gln442Ter nonsense variant and the p.Cys487Arg missense variant reported here, improves the sensitivity of genetic screening, particularly for populations in which these variants may be enriched. For families who carry such variants, a precise molecular diagnosis enables informed reproductive planning, including the possibility of prenatal or preimplantation genetic testing. It also spares patients the ordeal of repeated ineffective treatments by closing the diagnostic loop early. The authors note that their findings provide additional clinical and genetic evidence for the molecular diagnosis of this rare disease, a modest phrasing that understates the real-world impact a confirmed genetic result can have on a family that has spent months or years without answers.

Published open access in BMC Pediatrics on 21 September 2026, the study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Affiliated Hospital of Zunyi Medical University, with written informed consent obtained from the legal guardians of all patients. The work was supported by the Master’s Student Research Initiation Fund of the Affiliated Hospital of Zunyi Medical University and the Guizhou Provincial Program on Commercialization of Scientific and Technological Achievements. For a disease this rare, case series like this one are the primary engine of medical knowledge, accumulating patient by patient and variant by variant. Each additional documented mutation sharpens the diagnostic lens for clinicians everywhere and brings the goal of early recognition, accurate genetic confirmation, and timely, correctly targeted treatment for children with hereditary thrombotic thrombocytopenic purpura one step closer to routine practice.

Subject of Research: Genetic variants underlying pediatric hereditary thrombotic thrombocytopenic purpura

Article Title: Clinical and genetic characteristics of pediatric hereditary thrombotic thrombocytopenic purpura: a case series of two novel ADAMTS13 variants and one previously reported variant

Article References: Wan, Y., Guo, X., Tian, R., Mao, Q., & Tan, M. (2026). Clinical and genetic characteristics of pediatric hereditary thrombotic thrombocytopenic purpura: a case series of two novel ADAMTS13 variants and one previously reported variant. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07704-7

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07704-7

Keywords: hereditary thrombotic thrombocytopenic purpura, ADAMTS13, novel variants, pediatric hematology, thrombocytopenia, von Willebrand factor, genetic diagnosis, rare disease, compound heterozygous, homozygous mutation, misdiagnosis, BMC Pediatrics

ITP is an autoimmune bleeding disorder in which the immune system destroys platelets and suppresses their production in the bone marrow. In children, the condition often resolves on its own, but a substantial minority develop persistent or chronic disease requiring second-line therapy. TPO-RAs, which stimulate platelet production by activating the thrombopoietin receptor on megakaryocytes, are recommended second-line treatments. The class includes oral agents such as eltrombopag and avatrombopag, and the injectable peptide-mimetic romiplostim. When one agent fails, guidelines have suggested that switching within the class, particularly from an oral drug to romiplostim, may still succeed, because the agents differ in structure, metabolism, and pharmacology.

That assumption, however, had never been rigorously tested in the specific scenario that matters most: children who have failed not just one but several oral TPO-RAs. The Chinese research team, led by Shuyue Dong and Yumeng Jia with senior authors Xiaoling Cheng and Runhui Wu, was able to examine this question thanks to a unique real-world circumstance. Romiplostim reached the market late in China, which meant that children there often received it only after prolonged exposure to, and failure of, multiple oral TPO-RAs. This sequencing created a natural experiment that would be difficult to construct deliberately.

The study was a single-center, retrospective, observational analysis of patients aged 1 to 18 years with persistent or chronic ITP who received romiplostim for at least four weeks. The researchers assessed clinical characteristics, prior therapies, platelet response, bleeding outcomes, the need for rescue therapy, and adverse drug reactions. The work was approved by the Medical Ethics Committee of Beijing Children’s Hospital, and all patients provided written informed consent. The study was registered as ChiCTR2400086099 and funded by the National Key R&D Program of China and the National Natural Science Foundation of China.

Sixteen patients were analyzed in total. Thirteen of them had refractory ITP and had previously used two or more TPO-RAs before starting romiplostim. The results in this refractory group were strikingly poor. Eleven of the thirteen showed no response to romiplostim at all, and the remaining two exhibited only a transient partial response. In other words, not a single child in the refractory cohort achieved a complete or durable response once multiple oral TPO-RAs had already failed. The clinical burden in this group was substantial: twelve of the thirteen patients experienced bleeding episodes, eight required rescue therapy, and all thirteen ultimately switched to other drugs after romiplostim also proved ineffective.

The remaining three patients told a very different story, and the contrast is central to the study’s message. These children chose romiplostim not because other TPO-RAs had failed to work, but because of practical concerns such as potential drug interactions or liver dysfunction, which are recognized limitations of oral agents like eltrombopag. Only one of the three had previously used eltrombopag. In this selected group, two of the three patients achieved a complete response, while one showed no response. The findings suggest that romiplostim retains real value when it is used as a genuine alternative rather than as a last resort within an exhausted drug class.

On the safety front, the news was unambiguously positive. No adverse drug reactions were observed in any of the sixteen patients during the study period. This is consistent with the generally favorable tolerability profile that romiplostim has shown in pediatric populations, and it confirms that the drug itself is not the problem. The issue, the authors argue, is not whether romiplostim is safe or even whether it can work in children with ITP, but whether it can work in children whose disease has already demonstrated resistance to multiple members of its own class.

That resistance pattern carries important biological implications. TPO-RAs all converge on the same molecular target, the thrombopoietin receptor, also known as c-Mpl. If a child’s platelet production pathway remains unresponsive to two or more agents that activate this receptor through different chemical scaffolds, the likelihood that a third agent hitting the same target will succeed appears low. The study’s data give that reasoning empirical weight: within-class switching after multiple failures produced essentially no durable responses. This challenges the common clinical habit of cycling through TPO-RA options sequentially and suggests that the time and exposure spent on further within-class trials may come at the cost of delaying more appropriate therapies.

The authors conclude that romiplostim remains a safe and effective option for carefully selected pediatric ITP patients, but that children who have failed multiple oral TPO-RAs derive minimal benefit from switching to it. Instead, they recommend prioritizing alternative therapies that target immune dysregulation, the underlying mechanism of the disease, rather than continuing to push on the same thrombopoietin receptor pathway. Such alternatives could include immunomodulatory or immunosuppressive approaches that address the autoimmune attack driving platelet destruction, although the study itself does not evaluate specific alternative regimens.

As with any retrospective, single-center study, the findings come with limitations. The cohort was small, with only sixteen patients, and the refractory subgroup of thirteen, while internally consistent, limits statistical precision. Retrospective designs are also vulnerable to selection bias, since the decision to try romiplostim after multiple failures reflected real-world clinical judgment rather than a randomized protocol. Nevertheless, the near-universal failure of romiplostim in the multiply pretreated group is difficult to dismiss as chance, and the real-world sequencing that Chinese late-market conditions created gives the observation unusual relevance for clinicians everywhere who face the same decision. For families navigating refractory pediatric ITP, the study offers a clear if sobering message: after multiple oral TPO-RA failures, the next step should probably not be another drug from the same shelf.

Subject of Research: Romiplostim switching after multiple oral thrombopoietin receptor agonist failures in pediatric refractory immune thrombocytopenia

Article Title: Is switching to romiplostim still worthwhile after failure of multiple oral TPO-RAs in pediatric refractory ITP?

Article References: Is switching to romiplostim still worthwhile after failure of multiple oral TPO-RAs in pediatric refractory ITP?. (n.d.). https://doi.org/10.1007/s00277-026-07174-y

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07174-y

Keywords: immune thrombocytopenia, romiplostim, eltrombopag, avatrombopag, TPO receptor agonists, pediatric hematology, refractory ITP, switching strategy, platelet response, drug safety, retrospective study, Beijing Children's Hospital

The research, published as an open-access paper in Annals of Hematology, assembled a retrospective observational cohort of 53 children with Down syndrome aged six months to 18 years who had been newly diagnosed with myeloid leukemia across a nationwide network of pediatric hematology centers. Rather than treating all of these patients as a single group, the investigators classified them into two biologically distinct categories following World Health Organization guidelines and the recommendations of the BFM-AML protocol, one of the most influential treatment frameworks in pediatric leukemia. The first group, accounting for 71.7 percent of the cohort or 38 children, had what the researchers call DS-ML, the Down syndrome-associated myeloid leukemia that arises through a characteristic developmental pathway unique to trisomy 21. The remaining 28.3 percent, 15 children, had standard AML-DS, meaning they developed the conventional acute myeloid leukemia subtypes that also occur in children without Down syndrome.

That distinction turned out to matter enormously. The mean age at diagnosis in the DS-ML group was 23 months, compared with 48 months in the standard AML-DS group, a difference that reached statistical significance with a p-value of 0.033. The age gap is not merely a demographic curiosity; it reflects the fundamentally different origins of the two diseases. Down syndrome-related myeloid leukemia typically emerges in early childhood, often following a precursor condition known as transient abnormal myelopoiesis, in which extra copies of genes on chromosome 21 interact with mutations in the GATA1 gene to drive abnormal blood cell production in infants. Standard acute myeloid leukemia, by contrast, arises through the same constellation of genetic lesions that drive leukemia in the general pediatric population, and it tends to appear later in childhood.

The survival figures tell the story in starkest terms. In the DS-ML group, the five-year overall survival was 84.1 percent, with a standard error of 6.0 percent, and the five-year event-free survival was 81.3 percent, with a standard error of 6.4 percent. For children with standard AML arising in the setting of Down syndrome, the outlook was dramatically worse: overall survival of 53.3 percent, with a standard error of 12.9 percent, and event-free survival of just 45.7 percent, with a standard error of 13.1 percent. Both differences were statistically significant, with p-values of 0.039 for overall survival and 0.025 for event-free survival. In plain terms, a child with Down syndrome-related myeloid leukemia in this cohort had roughly a one-in-six chance of not surviving five years, while a child with standard acute myeloid leukemia and Down syndrome faced closer to a coin flip.

Complete remission rates followed the same pattern. Children in the DS-ML group achieved complete remission significantly more often than those in the standard AML-DS group, and the authors report that remission, overall survival, and event-free survival were all significantly higher in the DS-ML group. This is consistent with a growing international consensus that Down syndrome-associated myeloid leukemia, despite its alarming statistical association with trisomy 21, is among the more curable forms of pediatric acute leukemia when treated with appropriately calibrated therapy. The disease is exquisitely sensitive to certain chemotherapy agents, particularly cytarabine and anthracyclines, which partly explains why reduced-intensity protocols can achieve excellent outcomes in this population.

But the same sensitivity cuts in a dangerous direction. Children with Down syndrome are notoriously vulnerable to the toxic effects of intensive chemotherapy, experiencing higher rates of severe mucositis, life-threatening infections, and early treatment-related mortality when exposed to the full-dose regimens designed for standard pediatric acute myeloid leukemia. This is precisely why the authors argue that differentiating DS-ML from standard AML-DS is not an academic exercise. Giving a child with the highly curable DS-ML an unnecessarily intensive regimen exposes them to unacceptable toxicity without adding benefit, while giving a child with standard AML-DS a reduced-intensity protocol designed for DS-ML risks undertreating a biologically aggressive disease, inviting relapse and death. Matching treatment intensity to the correct diagnosis, the authors conclude, will increase survival by reducing both early mortality and relapse risk.

The study’s design reflects both the strengths and the inherent constraints of rare-disease research in pediatric hematology. Because Down syndrome-related myeloid leukemia is uncommon, no single center can accumulate a meaningful cohort, so the Turkish Pediatric Hematology Association coordinated data collection across a broad network of university hospitals, training and research hospitals, and children’s hospitals spanning the country, from Bursa Uludag University, which served as the coordinating institution, to centers in Izmir, Kocaeli, Samsun, Mersin, Diyarbakir, Malatya, Trabzon, Sakarya, Istanbul, Aydin, and Ankara. The retrospective design relied on anonymized data from electronic medical records, and the Institutional Review Board of Bursa Uludag University Health Research Ethics Committee waived the requirement for informed consent, approving the study in 2025 under decision number 2025/996/21-12. A biostatistician from Bursa Uludag University supported the analysis, lending methodological rigor to the comparison of survival curves between the two diagnostic groups.

What makes this contribution particularly valuable is the scarcity of published data that treat the two diseases as separate entities. Much of the existing literature has historically lumped all myeloid leukemia in children with Down syndrome together, obscuring the prognostic gulf between them. By explicitly separating DS-ML from standard AML-DS and reporting clinical and laboratory features, survival, relapse, and mortality rates for each group independently, the Turkish investigators have added a dataset that clinicians designing national treatment protocols can draw upon directly. The findings align with the broader biological understanding that trisomy 21 reshapes fetal hematopoiesis in ways that create a unique leukemic pathway, one that is fundamentally different from the mutational events driving de novo acute myeloid leukemia, even when both diseases occur in the same chromosomal context.

The implications extend beyond Turkey. As pediatric leukemia consortia worldwide continue to refine risk-stratified treatment algorithms, the Turkish cohort provides real-world evidence that the diagnostic fork between DS-ML and standard AML-DS is a genuine prognostic dividing line, not a subtle statistical nuance. For families, the message is one of cautious optimism: a child with Down syndrome who develops the characteristic myeloid leukemia of early childhood has a strong chance of long-term cure with modern, appropriately tailored therapy. For the smaller group of children whose leukemia follows the standard biological route, the study is a call for vigilance, closer monitoring, and consideration of more intensive therapeutic strategies. In an era when precision medicine is often equated with genomic sequencing, this work is a reminder that sometimes the most powerful precision tool is simply recognizing that two diseases sharing a name and a chromosome are, in every way that matters for survival, entirely different.

Subject of Research: Outcomes of myeloid leukemia in children with Down syndrome, comparing Down syndrome-associated myeloid leukemia with standard acute myeloid leukemia in a multicenter Turkish cohort

Article Title: Outcomes of down syndrome-related myeloid leukemia in Turkiye: a multicenter retrospective observational cohort study by the Turkish Pediatric Hematology Association

Article References: Düzenli Kar, Y., Ören, H., Sezgin Evim, M., Zengin, E., Gün, E., Karadaş, N., Yılmaz Karapınar, D., Albayrak, C., Ünal, S., Karahan, F., Söker, M., Uzel, V. H., Akyay, A., Öncül, Y., Bahadır, A., Orhan, M. F., Çakı Kılıç, S., Tufan Taş, B., Güler Kazancı, E., … Meral Güneş, A. (2026). Outcomes of down syndrome-related myeloid leukemia in Turkiye: a multicenter retrospective observational cohort study by the Turkish Pediatric Hematology Association. Annals of Hematology, 105(10), Article 422. https://doi.org/10.1007/s00277-026-07245-0

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07245-0

Keywords: Down syndrome, myeloid leukemia, acute myeloid leukemia, pediatric hematology, overall survival, event-free survival, trisomy 21, chemotherapy intensity, retrospective cohort study, Turkish Pediatric Hematology Association, complete remission, childhood cancer

Hydroxyurea has long been the cornerstone disease-modifying therapy for sickle cell anemia, the homozygous HbSS or HbSβ0-thalassemia genotypes that produce the most severe disease course. The drug works partly by reactivating fetal hemoglobin production, reducing the polymerization of sickle hemoglobin that drives red cell sickling, painful crises, and organ damage. Yet despite decades of clinical use, the precise relationship between dose and both clinical benefit and hematologic harm has remained uncertain, particularly across the diverse populations in which the disease is now treated.

To resolve this, the researchers conducted a systematic review and one-stage multilevel dose-response meta-analysis encompassing randomized trials, nonrandomized comparative studies, and longitudinal cohorts of children and adults with sickle cell disease. The quantitative synthesis focused principally on sickle cell anemia, with hydroxyurea dose expressed in mg/kg/day and achieved or maintenance doses preferred over starting doses. The primary benefit outcome was the rate of recurrent vaso-occlusive crises, while the primary safety outcomes were annual risks of severe or treatment-limiting neutropenia and thrombocytopenia, the two cytopenias that most often force dose reductions or discontinuation.

The modeling strategy was unusually rigorous. The team fitted Emax maximum-effect dose-response models as their primary analysis, testing linear and dose-independent alternatives in sensitivity analyses, and prespecified a decision rule requiring predicted annual neutropenia risk of no more than 5 percent and thrombocytopenia risk of no more than 3 percent, with at least an 80 percent simulation-derived probability that both criteria would be met simultaneously. Any eligible dose also had to retain near-optimal crisis control.

The results revealed a striking asymmetry between benefit and risk across the dose range. Empirical support for the primary analysis clustered between 20 and 28 mg/kg/day, and within that window recurrent vaso-occlusive crisis rates continued to fall, from a predicted 39.8 events per 100 person-years at 20 mg/kg/day to 32.5 at 28 mg/kg/day. Critically, the data showed no efficacy plateau: the Emax ED50 hit the upper limit of the prespecified search grid, and a simpler linear model actually fit marginally better, suggesting that whatever additional crisis reduction higher doses confer had not yet been exhausted within the observed range.

Safety told a different story. Predicted annual risk of severe or treatment-limiting neutropenia climbed steeply and early, from 1.98 percent at 20 mg/kg/day to 3.74 percent at just 21.5 mg/kg/day and 5.63 percent at 22.5 mg/kg/day. Thrombocytopenia, by contrast, remained uncommon and showed little dose dependence. Under the prespecified joint safety rule, the probability that both criteria were met was 87.1 percent at 20 mg/kg/day, 85.6 percent at 21 mg/kg/day, but only 77.8 percent at 21.5 mg/kg/day, failing the 80 percent threshold. The authors cautioned that because safety evidence was sparse and the joint classification depended partly on the relation between the two safety models, the low-20-mg/kg/day range should be read as an approximate safety transition rather than a precise toxicity threshold.

Within the empirically supported range, the lowest modeled recurrent crisis rate occurred at 28 mg/kg/day, and the unconstrained composite-benefit maximum at 25.5 mg/kg/day, but neither could clear the safety bar. Twenty-one mg/kg/day emerged as the highest dose satisfying the analytical rule, and the rounder conventional increment of 20 mg/kg/day was selected as the population reference dose, chosen from standard 2.5-mg/kg/day increments for practical prescribing.

The certainty of evidence behind these estimates was graded as very low for all three outcomes—recurrent crises, neutropenia, and thrombocytopenia—underscoring how much uncertainty remains. The review was prospectively registered with PROSPERO, and the authors emphasize that their decision framework, rather than any single trial, is what allows conflicting and sparse evidence to be converted into an actionable population-level recommendation.

Perhaps the most important clinical message is what the reference dose is not. The authors explicitly state that 20 mg/kg/day is neither a maximum tolerated dose nor a ceiling for treatment. Because crisis rates kept declining above 20 mg/kg/day, higher doses may well be appropriate for individual patients who need further clinical benefit, provided hematologic tolerance, adherence, and laboratory monitoring permit careful escalation. In resource-limited settings where laboratory surveillance is constrained, however, the population-level framework offers a defensible default that maximizes expected benefit while keeping predicted severe cytopenia risks within prespecified limits.

For the millions of people living with sickle cell anemia worldwide, most of them in sub-Saharan Africa, the findings translate decades of fragmented trial evidence into a single, transparent, quantitatively justified starting point for therapy—and a clear signal that the field still needs better safety data to push the benefit curve further.

Subject of Research: Dose-response relationship of hydroxyurea therapy in sickle cell anemia

Article Title: Hydroxyurea dosing in sickle cell anemia: a systematic review, dose-response meta-analysis, and population-level benefit-risk assessment

Article References: Hydroxyurea dosing in sickle cell anemia: a systematic review, dose-response meta-analysis, and population-level benefit-risk assessment. (n.d.). https://doi.org/10.1186/s12887-026-07679-5

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07679-5

Keywords: hydroxyurea, sickle cell anemia, dose-response meta-analysis, vaso-occlusive crisis, neutropenia, thrombocytopenia, benefit-risk assessment, systematic review, fetal hemoglobin, pediatric hematology, BMC Pediatrics, drug dosing